background
season
peak
asthma
exacerb
fall
previous
report
associ
fall
exacerb
viral
respiratori
tract
infect
rti
remain
uncertain
object
investig
number
fall
exacerb
incid
rti
pediatr
asthmat
popul
use
athom
mucu
collect
methodolog
method
multicent
random
doubleblind
parallelgroup
exploratori
studi
children
year
age
clinic
diagnosi
asthma
requir
use
inhal
corticosteroid
morn
peak
expiratori
flow
predict
histori
asthma
exacerb
previou
respiratori
viral
season
elig
enrol
subject
random
receiv
fluticason
propionatesalmeterol
fpsal
mcg
fp
mcg
prior
start
school
subject
collect
mucu
sampl
use
athom
kit
experienc
respiratori
symptom
mucu
sampl
obtain
symptomat
period
analyz
common
respiratori
virus
multiplex
polymeras
chain
reaction
number
exacerb
requir
system
corticosteroid
record
result
total
fpsal
n
fp
n
subject
random
includ
intenttotreat
popul
complet
studi
mucu
sampl
collect
test
posit
virus
posit
sampl
associ
asthma
exacerb
exacerb
infrequ
subject
report
exacerb
total
advers
event
report
subject
conclus
suscept
popul
fall
asthma
exacerb
rate
children
low
despit
frequent
detect
viral
rti
gsk
id
associ
season
asthma
exacerb
viral
respiratori
infect
pediatr
popul
receiv
inhal
corticosteroid
therapi
without
longact
betaadrenoceptor
agonist
random
studi
primari
schoolag
children
frequent
present
asthma
sudden
deterior
health
statu
associ
viral
respiratori
tract
infect
rti
result
sign
airway
obstruct
cough
wheez
fall
season
peak
asthma
exacerb
report
mani
studi
wide
associ
human
rhinoviru
hrv
infect
sever
asthma
exacerb
requir
use
system
corticosteroid
sc
major
caus
diseas
suffer
morbid
account
abbrevi
ae
advers
event
cact
childhood
asthma
control
test
er
emerg
room
fpsal
fluticason
propionatesalmeterol
combin
fp
fluticason
propion
hrv
human
rhinoviru
ic
inhal
corticosteroid
itt
intenttotreat
pef
peak
expiratori
flow
rtpcr
realtim
polymeras
chain
reaction
rsv
respiratori
syncyti
viru
rti
respiratori
tract
infect
sae
seriou
advers
event
sc
system
corticosteroid
studi
fund
glaxosmithklin
signific
asthmarel
healthcar
cost
usa
main
risk
factor
predictor
futur
exacerb
pediatr
asthma
popul
past
histori
fall
exacerb
particularli
vulner
respiratori
infect
upon
return
school
studi
set
identifi
pediatr
popul
year
age
least
week
prior
return
school
consid
risk
season
exacerb
base
recent
prior
histori
exacerb
requir
treatment
sc
emerg
room
er
visit
hospit
investig
viral
etiolog
exacerb
occur
fall
season
studi
util
athom
symptomdriven
method
collect
mucu
sampl
subsequ
analyz
viral
content
exacerb
rare
event
studi
design
demonstr
statist
signific
differ
exacerb
rate
treatment
group
rather
explor
relationship
treatment
respiratori
symptom
exacerb
viral
etiolog
mucu
sampl
collect
trigger
presenc
worsen
asthma
cold
symptom
sampl
analyz
realtim
polymeras
chain
reaction
rtpcr
presenc
identif
viru
date
mucu
collect
asthma
andor
cold
symptom
pattern
viral
etiolog
date
exacerb
treatment
facilit
investig
associ
viral
presenc
asthma
exacerb
first
studi
atrisk
pediatr
popul
prospect
explor
viral
etiolog
associ
fall
asthma
exacerb
symptomdriven
collect
mucu
sampl
differ
mani
previou
studi
nasal
mucu
sampl
collect
real
time
children
follow
report
moderatetosever
respiratori
symptom
rather
time
shortli
asthma
exacerb
studi
design
allow
frequent
mucu
collect
beyond
time
exacerb
studi
allow
observ
viral
infect
pattern
throughout
fall
period
result
present
demonstr
feasibl
athom
mucu
collect
random
clinic
trial
set
provid
evid
major
viral
infect
children
treat
control
medic
persist
asthma
caus
exacerb
asthma
boy
girl
year
old
attend
daycar
school
clinic
diagnosi
asthma
requir
use
inhal
corticosteroid
ic
monoor
combin
control
medic
elig
inclus
studi
subject
requir
morn
peak
expiratori
flow
pef
predict
baselin
histori
exacerb
asthma
previou
respiratori
viral
season
septemb
requir
use
sc
asthmarel
urgent
care
visit
er
visit
hospit
period
exclus
criteria
includ
histori
lifethreaten
asthma
previou
month
evid
unstabl
asthma
week
prior
random
worsen
asthma
week
prior
screen
includ
use
sc
multicent
random
doubleblind
parallelgroup
studi
design
explor
relationship
number
exacerb
viral
rti
fall
viral
season
septemb
gsk
studi
identifi
enrol
plan
subject
across
site
subject
random
receiv
fluticason
propionatesalmeterol
fpsal
mcg
fp
mcg
deliv
twice
daili
via
disku
devic
week
subject
prescreen
elig
random
august
august
ensur
studi
treatment
administ
least
week
prior
subject
return
school
allow
inclus
subject
may
taken
summer
holiday
control
medic
subject
requir
compliant
use
control
medic
time
random
type
school
attend
eg
tradit
calendar
yearround
etc
whether
session
time
random
collect
nonstudi
ic
monoor
combin
medic
suspend
durat
studi
shortact
b
agonist
medic
replac
albuterol
subject
requir
withhold
albuterol
h
prestudi
visit
placebo
group
includ
studi
popul
requir
therapi
time
studi
entri
studi
protocol
inform
consent
assent
document
approv
either
central
institut
review
board
independ
ethic
committe
particip
site
written
inform
consent
obtain
parent
subject
prior
studyspecif
procedur
addit
ageappropri
assent
form
use
inform
studi
particip
studi
carri
accord
declar
helsinki
complianc
intern
confer
harmonis
good
clinic
practic
guidelin
fund
studi
provid
glaxosmithklin
subject
assign
treatment
accord
computergener
random
schedul
telephon
call
interact
voic
respons
system
subsequ
visit
telephon
call
made
treatment
pack
number
investig
subject
blind
treatment
assign
caregiv
subject
kept
daili
electron
diari
ediari
record
asthma
measur
includ
morn
pef
asthma
symptom
use
scale
nighttim
awaken
due
asthma
rescu
medic
use
miss
school
due
asthma
upper
respiratori
symptom
ie
cold
symptom
use
scale
ediari
respons
trigger
mucu
sampl
collect
throughout
studi
describ
inform
regard
allergi
statu
presenceabs
type
collect
parent
report
baselin
diari
measur
defin
mean
diari
score
collect
day
immedi
follow
random
visit
assess
whether
asthma
exacerb
associ
respiratori
viru
infect
subject
prompt
symptomdriven
basi
collect
mucu
sampl
subject
ediari
alert
subject
criteria
athom
nasal
mucu
sampl
collect
met
subject
parent
train
athom
collect
freezer
storag
mucu
sampl
use
methodolog
previous
report
protocol
defin
symptom
trigger
mucu
collect
includ
presenc
moderatetosever
upper
respiratori
symptom
ie
cold
symptom
worsen
asthma
worsen
asthma
symptom
trigger
follow
asthma
symptom
score
consecut
day
increas
rescu
medic
use
baselin
morn
pef
determin
stabil
limit
consecut
day
nighttim
awaken
due
asthma
consecut
night
morn
pef
stabil
limit
defin
decreas
mean
morn
pef
determin
data
collect
first
week
studi
ediari
alert
subject
collect
mucu
sampl
within
given
period
presenc
moderatetosever
upper
respiratori
coldlik
symptom
also
collect
daili
ediari
present
mild
clearli
present
moder
sever
uncomfort
sever
interf
sleep
activ
onset
date
cold
defin
retrospect
first
day
report
moderatetosever
upper
respiratori
symptom
report
ediari
ie
score
respect
cold
period
defin
cold
onset
day
follow
day
cold
onset
day
separ
least
day
cold
period
overlap
end
studi
sampl
ship
univers
wisconsin
viral
analysi
viral
analysi
conduct
previous
report
use
multiplex
rtpcr
primari
measur
efficaci
number
asthma
exacerb
occur
fall
viral
studi
period
august
exacerb
defin
per
protocol
deterior
asthma
requir
use
outpati
sc
tablet
suspens
inject
urgent
care
visit
hospit
er
visit
secondari
efficaci
measur
includ
assess
symptom
sever
durat
incid
exacerb
associ
moderatetosever
upper
respiratori
infect
control
statu
assess
use
childhood
asthma
control
test
cact
clinic
visit
baselin
week
cact
valid
questionnair
complet
subject
question
subject
parentleg
guardian
question
investig
calcul
total
score
transcrib
clinic
trial
report
score
indic
asthma
may
well
control
safeti
assess
advers
event
ae
seriou
ae
sae
monitor
throughout
studi
day
last
clinic
visit
followup
phone
call
studi
design
exploratori
therefor
hypothesi
test
consid
descript
rather
inferenti
consequ
multipl
adjust
result
hypothesi
test
made
descript
statist
analysi
use
sa
version
softwar
unix
report
environ
formal
power
sampl
size
calcul
sampl
size
subject
per
treatment
chosen
support
natur
asthma
exacerb
infrequ
occur
event
analysi
popul
intenttotreat
itt
popul
includ
subject
random
studi
drug
secondari
measur
efficaci
summar
treatment
group
includ
sever
asthma
symptom
associ
posit
viral
sampl
exacerb
associ
posit
viral
sampl
exacerb
associ
posit
viral
sampl
analyz
manner
primari
efficaci
measur
total
subject
fpsal
n
fp
n
center
unit
state
random
includ
itt
popul
complet
full
studi
fpsal
n
fp
n
patient
disposit
reason
subject
withdraw
shown
fig
mean
age
studi
popul
year
mean
durat
asthma
year
major
studi
popul
attend
tradit
calendar
school
yet
return
back
school
time
random
tabl
total
cold
period
event
defin
moderatetosever
asthma
symptom
day
report
subject
report
least
one
cold
period
event
common
reason
ediari
alert
mucu
sampl
collect
decreas
pef
stabil
limit
event
rescu
medic
use
event
tabl
studi
subject
collect
least
one
mucu
sampl
studi
total
mucu
sampl
collect
analyz
number
cold
period
event
ediari
alert
mucu
sampl
collect
similar
treatment
group
data
shown
total
mucu
sampl
test
posit
least
one
respiratori
viru
total
number
viru
posit
sampl
hrv
posit
fig
addit
hrv
type
conduct
next
frequent
detect
virus
parainfluenzaviru
coronaviru
major
virusposit
sampl
test
posit
presenc
viru
sampl
test
posit
viru
tabl
studi
subject
experienc
least
one
exacerb
total
exacerb
report
mucu
sampl
collect
within
day
exacerb
ie
day
prior
exacerb
onset
day
post
exacerb
sampl
viru
posit
rhinoviru
posit
therefor
viru
posit
mucu
sampl
collect
associ
asthma
exacerb
exacerb
mucu
sampl
collect
within
period
surround
exacerb
fig
total
subject
wellcontrol
asthma
baselin
cact
score
compar
baselin
control
statu
subject
exacerb
studi
note
subject
exacerb
report
wellcontrol
cact
baselin
compar
exacerb
studi
week
proport
patient
wellcontrol
statu
cact
increas
tabl
period
surround
exacerb
fpsal
compar
fp
treatment
associ
reduct
rescu
medic
use
asthma
symptom
fig
morn
pef
similarli
variabl
treatment
group
day
surround
exacerb
similar
adhoc
analysi
conduct
examin
paramet
associ
virusassoci
exacerb
result
inconclus
due
low
number
virusassoci
exacerb
data
shown
total
subject
report
ae
experienc
drugrel
ae
total
nonfat
sae
report
subject
one
hospit
due
asthma
exacerb
report
sae
includ
gastroenter
syncop
subject
rsv
pneumonia
respiratori
distress
statu
asthmaticu
subject
sae
consid
treatment
relat
death
either
treatment
group
total
subject
experienc
ae
consid
nonseri
lead
studi
withdraw
deterior
asthma
n
abnorm
behavior
n
sae
lead
studi
withdraw
includ
rsv
pneumonia
respiratori
distress
statu
asthmaticu
subject
common
ae
report
includ
upper
rti
headach
cough
pyrexia
nasopharyng
ae
similar
incid
treatment
group
except
sinus
commonli
report
fpsal
compar
fp
common
drugrel
ae
headach
upper
rti
common
etiolog
exacerb
asthma
children
viral
rti
sever
risk
viral
associ
exacerb
may
influenc
factor
includ
atop
statu
previou
histori
exacerb
pathogen
infect
viru
exposur
allergen
medic
taken
medic
adher
sever
vitro
studi
suggest
synergist
benefit
asthma
treatment
includ
ic
combin
longact
betaadrenoceptor
agonist
hrv
studi
set
prospect
assess
frequenc
etiolog
exacerb
schoolag
subject
fall
viral
epidem
background
fp
fpsal
mainten
therapi
studi
also
address
confirm
feasibl
use
athom
collect
mucu
sampl
detect
viral
etiolog
studi
viral
rti
subject
asthma
major
studi
popul
experienc
moderatetosever
cold
symptom
least
fall
studi
period
base
time
sinc
random
first
report
moderatetosever
cold
symptom
occur
second
third
week
septemb
continu
throughout
treatment
period
obviou
peak
worsen
asthma
symptom
report
throughout
treatment
period
obviou
peak
report
virus
detect
mucu
sampl
collect
frequenc
similar
result
found
recent
studi
studi
employ
symptomdriven
mucu
collect
viral
detect
frequenc
suggest
caus
viral
infect
eg
allergen
air
pollut
etc
also
contribut
respiratori
symptom
sampl
posit
virolog
rhinoviru
common
respiratori
viru
identifi
find
consist
report
fall
studi
asthma
number
exacerb
seen
fall
studi
treatment
period
low
children
experienc
exacerb
requir
treatment
sc
hospit
notabl
consid
studi
conduct
peak
viral
season
septembereearli
decemb
popul
consid
higher
risk
exacerb
base
past
exacerb
histori
frequenc
viral
associ
exacerb
similar
viralassoci
exacerb
rate
report
studi
conduct
outpati
set
emerg
depart
hospit
strength
studi
differenti
previou
studi
virusinduc
exacerb
prospect
intervent
studi
blind
medic
provid
particip
adher
asthma
control
therapi
monitor
nasal
sampl
symptomdriven
studi
design
contrast
observ
crosssect
cohort
studi
adher
asthma
control
medic
preced
exacerb
presum
low
nasal
sampl
collect
schedul
time
addit
strength
studi
includ
design
requir
popul
enter
studi
period
earli
august
enabl
treatment
entir
studi
popul
minimum
week
prior
start
tradit
school
calendar
also
studi
employ
time
mucu
sampl
collect
driven
presenc
moderatetosever
upper
respiratori
symptom
andor
presenc
sign
worsen
asthma
demonstr
symptomdriven
athom
sampl
collect
feasibl
random
control
trial
set
even
though
mucu
collect
depend
parent
child
complianc
procedur
athom
featur
allow
accur
classif
exacerb
term
viral
etiolog
studi
also
use
stringent
gener
accept
definit
asthma
exacerb
requir
either
sc
use
acut
care
visit
hospit
accord
statement
american
thorac
societi
european
respiratori
societi
asthma
control
exacerb
one
limit
studi
inabl
detect
treatment
differ
result
exploratori
design
low
number
viral
rtiassoci
exacerb
observ
studi
popul
anoth
limit
lack
placebo
arm
would
enabl
assess
effect
asthma
mainten
treatment
viral
etiolog
exacerb
rate
previou
random
pediatr
studi
retrospect
cohort
analys
popul
similar
exacerb
risk
impair
demonstr
approxim
subject
experi
exacerb
fall
higher
exacerb
rate
report
current
studi
fp
fp
sal
mainten
therapi
placebocontrol
studi
requir
examin
effect
mainten
therapi
exacerb
asthma
conclus
studi
result
indic
larg
major
viral
rti
associ
fall
exacerb
asthma
atrisk
children
control
therapi
demonstr
feasibl
util
viral
monitor
exacerb
therapeut
trial
find
suggest
addit
factor
relat
viru
eg
rv
speci
environ
andor
host
help
determin
risk
virusinduc
exacerb
understand
relationship
exacerb
asthma
viral
rti
may
provid
new
insight
improv
therapeut
strategi
aim
manag
asthma
exacerb
disclosur
cm
prazma
da
stempel
employe
glaxosmithklin
stocksshar
glaxosmithklin
involv
studi
design
data
collect
analysi
ba
prillaman
employe
glaxosmithklin
hold
stock
glaxosmithklin
employe
parexel
involv
studi
design
data
collect
analysi
je
gern
paid
employe
univers
wisconsin
involv
studi
design
advis
mucu
sampl
data
collect
process
techniqu
viral
data
analysi
conduct
univers
wisconsinemadison
sf
weinstein
particip
studi
investig
clinic
trial
clinic
paid
particip
studi
sf
weinstein
involv
studi
design
enrol
subject
clinic
trial
data
collect
subject
sf
weinstein
studi
site
contribut
overal
studi
data
author
particip
data
analysi
interpret
data
initi
develop
manuscript
decis
submit
final
manuscript
public
honorarium
grant
form
payment
made
author
contribut
manuscript
summari
mean
chang
daili
asthma
symptom
rescu
medic
use
itt
popul
chang
day
mean
daili
asthma
symptom
score
day
prior
day
follow
exacerb
b
chang
day
mean
daili
rescu
medic
use
day
prior
day
follow
exacerb
mean
valu
determin
subject
treatment
group
day
period
surround
exacerb
first
day
exacerb
treatment
ic
determin
day
fp
fluticason
propion
fpsal
fluticason
propion
salmeterol
itt
intenttotreat
